Molly Freeman on SBRT Aftercare for Patients with Lung Cancer

Patients with metastatic squamous non–small cell lung cancer experienced a clinically meaningful survival benefit when treated with pembrolizumab in combination with chemotherapy.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

In both the KEYNOTE-641 and KEYNOTE-789 trials, pembrolizumab, in addition to standard therapies, did not improve survival outcomes in their target populations.

Findings from a phase 2/3 trial found better disease-free and overall survival outcomes with radiation plus docetaxel vs radiation alone in head and neck squamous cell carcinoma.